BlueRidge Life Sciences
Consultancy providing integrated scientific, regulatory, engineering, and commercialization services across pharmaceuticals, biologics, medical devices, chemicals, foods, and consumer products. Core capabilities include nonclinical safety and toxicology, clinical development and adaptive trial design, regulatory strategy and submission support, epidemiology and biostatistics, health economics and market-access planning, cold-chain engineering and shipping validation, exposure science, human-centered device design and human factors, and lifecycle program and risk management.
Industries
Nr. of Employees
medium (51-250)
BlueRidge Life Sciences
Westlake Village, California, United States, North America
Services
Design and oversight of nonclinical toxicology programs, pathology interpretation, immunotoxicology and genetic toxicology support to enable regulatory submissions.
Regulatory planning, authority interactions, submission preparation and strategic advice for pediatric, rare disease, device, and combination-product pathways; coordination of multi-jurisdictional filings.
Study design, statistical analyses, RWD/RWE generation, and publication strategy to support evidence generation and regulatory documentation.
Cold-chain design, worst-case shipping simulations, transport simulation studies that concurrently simulate temperature excursions and mechanical hazards, transport validation study design, operational and performance qualification, and data analysis for temperature-sensitive therapeutics aligned to regulatory expectations for filings.
User needs analysis and validated prioritization, human factors/usability engineering, Design History File preparation, platform DHF development, and regulatory strategy for combination products and standalone devices.
Evidence strategy, health economic modeling, market access assessments, pricing and reimbursement strategy, and preparation of payer and HTA communications to support product launch.
Design and oversight of nonclinical toxicology programs, pathology interpretation, immunotoxicology and genetic toxicology support to enable regulatory submissions.
Regulatory planning, authority interactions, submission preparation and strategic advice for pediatric, rare disease, device, and combination-product pathways; coordination of multi-jurisdictional filings.
Study design, statistical analyses, RWD/RWE generation, and publication strategy to support evidence generation and regulatory documentation.
Cold-chain design, worst-case shipping simulations, transport simulation studies that concurrently simulate temperature excursions and mechanical hazards, transport validation study design, operational and performance qualification, and data analysis for temperature-sensitive therapeutics aligned to regulatory expectations for filings.
User needs analysis and validated prioritization, human factors/usability engineering, Design History File preparation, platform DHF development, and regulatory strategy for combination products and standalone devices.
Evidence strategy, health economic modeling, market access assessments, pricing and reimbursement strategy, and preparation of payer and HTA communications to support product launch.
Expertise Areas
- Clinical trial management and adaptive trial design
- Nonclinical toxicology and pathology
- Regulatory strategy and global submission coordination (drugs, devices, combination products)
- Epidemiology, biostatistics and real-world evidence generation
Key Technologies
- Physiologically based pharmacokinetic (PBPK) modeling
- Quantitative structure-activity relationship (QSAR) modeling
- In silico toxicology and predictive analytics
- Real-world data (RWD) / real-world evidence (RWE) analytics
News & Updates
Announcement of the appointment of Ian Kelly as CEO and summary of company services and strategy.
Announcement of hires expanding pathology and nonclinical safety capabilities to support regulatory toxicology and pathology work.
Industry article on strategic planning for drug delivery systems and integrated development planning.
Announcement that a company scientist co-authored a peer-reviewed study on clinical, economic, and quality-of-life outcomes in overweight and obese populations.
Discussion and analysis of redacted FDA and EMA public documents to highlight agency expectations for shipping validation and to inform transport simulation study design.
Discussion of validated and prioritized user-needs mapping and its role in guiding design and usability engineering for combination products.
Announcement of the appointment of Ian Kelly as CEO and summary of company services and strategy.
Announcement of hires expanding pathology and nonclinical safety capabilities to support regulatory toxicology and pathology work.
Industry article on strategic planning for drug delivery systems and integrated development planning.
Announcement that a company scientist co-authored a peer-reviewed study on clinical, economic, and quality-of-life outcomes in overweight and obese populations.
Discussion and analysis of redacted FDA and EMA public documents to highlight agency expectations for shipping validation and to inform transport simulation study design.
Discussion of validated and prioritized user-needs mapping and its role in guiding design and usability engineering for combination products.